Add Yahoo as a preferred source to see more of our stories on Google. Leaders from the Assembly of First Nations (AFN) and ...

We extend our profound appreciation to President Bola Ahmed Tinubu for providing the overarching leadership climate that ...

The coalition said the video of police arresting a 15-year-old appeared to show law enforcement contradicting its code of ...

The Director-General of the Kanu Nwankwo Football Academy (KIFA), Hon. Dabo Ajibade, will lead a delegation to the grand ...

The address, delivered on the occasion of Dr B.R. Ambedkar’s birth anniversary, highlighted the architect of the Constitution as a guiding force for India’s journey toward becoming a developed nation ...

Game engine maker Unity, whose tech powers many games, from 2025 hits like Hollow Knight: Silksong and Peak to anticipated 2026 offerings like Mouse: P.I. for Hire and Replaced (both of which are due ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

I have been patiently waiting for a buying opportunity in Unity (U), and the apocalypse in software stocks has finally provided one. Sentiment is very low in software as investors appear concerned ...

Explore how next-gen game engines like Unity and Unreal Engine technology are evolving, powering advanced graphics, cross-platform development, and real-time 3D experiences across games and beyond.

GameSpot may get a commission from retail offers. Over a decade after a disastrous debut plagued with faceless NPCs and frame rate issues, Assassin's Creed Unity is rounding out its comeback story ...

Ubisoft shared its upcoming plans for the Assassin's Creed franchise today. Along with the news of a remake for its piratical entry, the game company also announced that a visual upgrade is coming for ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.